Wedbush Lifts Earnings Estimates for Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at Wedbush upped their FY2027 earnings estimates for Neurocrine Biosciences in a report issued on Monday, December 23rd. Wedbush analyst L. Chico now expects that the company will post earnings per share of $14.46 for the year, up from their previous estimate of $13.11. Wedbush currently has a “Outperform” rating and a $148.00 target price on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.94 per share. Wedbush also issued estimates for Neurocrine Biosciences’ FY2028 earnings at $17.74 EPS.

A number of other brokerages have also issued reports on NBIX. Barclays upped their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday. HC Wainwright restated a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets dropped their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $166.29.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $136.53 on Wednesday. The stock’s fifty day moving average is $124.79 and its 200-day moving average is $130.60. The stock has a market capitalization of $13.82 billion, a PE ratio of 36.60 and a beta of 0.34. Neurocrine Biosciences has a 52 week low of $110.95 and a 52 week high of $157.98.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NBIX. Ashton Thomas Private Wealth LLC bought a new stake in shares of Neurocrine Biosciences during the 2nd quarter valued at approximately $28,000. Innealta Capital LLC acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter worth approximately $30,000. Blue Trust Inc. boosted its position in Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares during the last quarter. Plato Investment Management Ltd boosted its position in shares of Neurocrine Biosciences by 44.1% during the 2nd quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock valued at $59,000 after purchasing an additional 130 shares in the last quarter. Finally, Truvestments Capital LLC bought a new position in shares of Neurocrine Biosciences during the 3rd quarter worth approximately $63,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares of the company’s stock, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the sale, the insider now directly owns 2,507 shares in the company, valued at $338,445. This represents a 30.32 % decrease in their position. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.